2 healthcare stocks to turn $10 into $100 by next year

Healthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence ( AI ) boom. Beyond their defensive characteristics, biotechnology companies developing treatments for cancer, diabetes and other diseases offer exposure to potentially significant long-term growth. While turning a small investment into a substantially larger one within a year would require exceptional returns, some smaller healthcare companies have catalysts that could attract investor interest in 2027. To this end, Finbold has identified the following two companies worth considering Recursion Pharmaceuticals (NASDAQ: RXRX) Recursion Pharmaceuticals (NASDAQ: RXRX ) could offer significant upside in 2027 as its AI-powered drug discovery platform advances through clinical development and attracts pharmaceutical partnerships.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to Finbold.